An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model"

Hong Anh T. Tu*, Mark H. Rozenbaum, Pieter T. de Boer, Albert C. Noort, Maarten J. Postma

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

14 Citations (Scopus)
81 Downloads (Pure)

Abstract

Background: To update a cost-effectiveness analysis of rotavirus vaccination in the Netherlands previously published in 2011.Methods: The rotavirus burden of disease and the indirect protection of older children and young adults (herd protection) were updated.Results: When updated data was used, routine infant rotavirus vaccination in the Netherlands would potentially become an even more cost-effective strategy than previously estimated with the incremental cost per QALY at only €3,000-4,000. Break-even total vaccination costs were indicated at €92-122, depending on the applied threshold.Conclusions: We concluded that the results on potentially favourable cost-effectiveness in the previous study remained valid, however, the new data suggested that previous results might represent an underestimation of the economic attractiveness of rotavirus vaccination.
Original languageEnglish
Article number54
Number of pages5
JournalBMC Infectious Diseases
Volume13
Issue number1
DOIs
Publication statusPublished - 30-Jan-2013
Externally publishedYes

Keywords

  • Cost-effectiveness analysis
  • Rotavirus vaccination
  • the Netherlands
  • ACUTE GASTROENTERITIS
  • UNITED-STATES
  • CHILDREN
  • HOSPITALIZATIONS
  • REDUCTION
  • ETIOLOGY
  • PROGRAM

Cite this